Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Parkinson's drug tested for eye disease

NCT ID NCT03197493

Disease control Sponsor: Snyder, Robert W., M.D., Ph.D., P.C. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests a drug called carbidopa-levodopa (Sinemet), typically used for Parkinson's disease, in people with wet age-related macular degeneration (AMD). It is a 9-month extension for 35 participants who completed an earlier study. The goal is to see if the drug can help maintain vision and reduce retinal swelling.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
carbidopa-levodopa (Sinemet)
What this could lead to
If it works, this could point toward a new oral treatment to help control vision loss in wet age-related macular degeneration.
What could go wrong
This is a small, early-phase extension study with only 35 participants. It may not show clear benefits, and the drug can cause side effects like nausea or dizziness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

35 people

The number who actually took part.

Started

Aug 2017

Finished

Jul 2020

Lead sponsor

An individual researcher

The lead sponsor is a named person rather than an organisation.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Completion of Protocol 002. 2. A diagnosis of AMd with choroidal neovascularization (CNV) in 1 eye. 3. Normal or Dry AMD of any grade in the second eye. 4. Age 50-85 years. 5. Willingness to maintain AREDS vitamin Supplements throughout the study, or remain off of these supplements for the duration of the study, if not taking them prior to the study. 6. Informed consent at visit 1, which is also Visit 5 of study 002. Exclusion criteria: 1. Any current use of L-DOPA containing medication or dopamine agonist medication, or any planned use of any of these agents, except for study medication, during the study; 2. Concurrent use of monoamine oxidase (MAO) inhibitors; 3. Any eye condition, disease, or history of trauma in either eye, which can impair vision, except cataract or cataract surgery; 4. BCVA worse than 20/60 in the better eye; 5. Wet AMD in the second eye; 6. Neurologic conditions which can impair vision; 7. Parkinson's Disease; 8. Significant orthostatic hypotension, defined as a drop in systolic blood pressure, immediately upon changing from the supine to standing position, of \>19 mmHg, or a symptomatic drop in systolic blood pressure, immediately upon changing from the supine to standing position; 9. Significant ECG abnormalities, as judged by the Investigator; 10. Estimated glomerular filtration rate (eGFR) \<20 ml/min; 11. Liver enzymes \>3 X the upper limit of normal; 12. HbA1C \>9.0; 13. Any other significant lab abnormalities, as judged by the Investigator. 14. Women of childbearing potential; 15. Known retinal hemorrhage; 16. Subjects who are not fluent in English.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Macula; degeneration are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

macular degeneration wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Macula; degeneration RETINA

Contacts and locations

Locations

  • Robert W Snyder, MD, PhD, PC

    Tucson, Arizona, 85712, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.